Verrica Stock Slips Before Jefferies as Cash Warning Shadows YCANTH Growth
Verrica Pharmaceuticals closed Tuesday at $5.80, down 2.2%, and last traded at $5.79 ahead of a June 4 investor presentation. The company reported $5 million in first-quarter revenue and a $9.7 million net loss, with $20.6 million in cash as of March 31. Analyst Raghuram Selvaraju rated the stock Buy with a $12 target. No new filings or product updates have been released in the past 48 hours.